Malaria has plagued humankind since our very evolution. It infects hundreds of millions of people every year and kills hundreds of thousands. Now, with the Covid-19 pandemic still raging on, the mosquito-borne illness is on our minds more than ever. Critically, with...
When a company first starts out, profitability can seem a long way off. But after years of hard work, pharmaceutical services firm Open Orphan (LON: ORPH) is hitting that benchmark in style. And not only that, but the firm is rewarding shareholders for their faith in...
Open Orphan (LON: ORPH) on Thursday announced not only strong annual results but also that spin-off Poolbeg is planning to seek admission to trading on London’s AIM market. The company explained that Poolbeg will primarily use the funds raised as part of its admission...
Open Orphan (LON: ORPH) is planning to spin off its non-core assets and direct energy towards its fast-growing hVIVO challenge studies unit, which just won a £3 million contract. The separation will maximise value for shareholders while taking advantage of a challenge...
Open Orphan (LSE:ORPH) advanced 3% to 23.7p on Monday morning after revealing a contract renewal expected to deliver “significant revenue” over the next 12 months. The specialist pharma services clinical research organisation announced that the deal had been made...
Open Orphan (LSE:ORPH) We may have entered a new year, but momentum at Open Orphan continues to build at pace. On Wednesday, the rapidly-growing pharma services firm and AIM darling announced that it had opened two new recruitment centres to screen potential...
The first volunteer has been dosed with a COVID-19 vaccine as part of hVIVO’s phase 1 clinical trial of COVI-VAC. Following on from its announcement in July last year, the CRO, part of Open Orphan (LSE: ORPH), has begun its randomised, double-blinded,...
Open Orphan PLC (LSE: ORPH) has recently extended a contract with a top-three global pharma company. Its Venn Life Services subsidiary, operating out of Breda, Netherlands, will provide chemistry, manufacturing, and control consultancy services to support the client’s...
Open Orphan (LSE: ORPH) subsidiary Venn Life Sciences has extended a consulting contract with a global pharma firm to support two vaccine development programmes. Venn’s Breda office in the Netherlands will handle chemistry, manufacturing and control duties for the...